Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes

6 Dec 2013

Abstract excerpt

Clinical experience with 5-azacytidine and decitabine treatment of myelodysplastic syndromes (MDS), complemented by biological and pharmacological studies, has revealed compelling mechanism of action differences compared with traditional myeloid cancer treatment mainstays such as cytarabine. For example, 5-azacytidine and decitabine produce remissions and better overall survival in MDS with high-risk chromosome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24319226
DOI: 10.1182/asheducation-2013.1.511

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomesPMID 24319226Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Differentiation therapy for myeloid malignancies: beyond cytotoxicity.Semantic proximity Read ↗

How recent advances in high-risk myelodysplastic syndrome physiopathology may impact future treatments.Semantic proximity Read ↗

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersSemantic proximity Read ↗

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell lineSemantic proximity Read ↗

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidineSemantic proximity Read ↗

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell LinesSemantic proximity Read ↗

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell lineSemantic proximity Read ↗

Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.Semantic proximity Read ↗

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.